Last reviewed · How we verify
Vonoprazan+tetracycline+furazolidone 7 days
Vonoprazan+tetracycline+furazolidone 7 days is a H. pylori eradication therapy (triple therapy) Small molecule drug developed by Xijing Hospital of Digestive Diseases. It is currently FDA-approved for Helicobacter pylori infection eradication.
This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone).
This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone). Used for Helicobacter pylori infection eradication.
At a glance
| Generic name | Vonoprazan+tetracycline+furazolidone 7 days |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | H. pylori eradication therapy (triple therapy) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker that raises gastric pH to optimize antibiotic efficacy. Tetracycline is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Furazolidone is a nitrofuran antimicrobial agent with activity against H. pylori. The 7-day regimen is designed to achieve high eradication rates in H. pylori infection.
Approved indications
- Helicobacter pylori infection eradication
Common side effects
- Nausea
- Diarrhea
- Abdominal discomfort
- Photosensitivity (tetracycline)
- Peripheral neuropathy (furazolidone)
Key clinical trials
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
- Vonoprazan Hp Dual or Triple Eradication Regimes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan+tetracycline+furazolidone 7 days CI brief — competitive landscape report
- Vonoprazan+tetracycline+furazolidone 7 days updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI
Frequently asked questions about Vonoprazan+tetracycline+furazolidone 7 days
What is Vonoprazan+tetracycline+furazolidone 7 days?
How does Vonoprazan+tetracycline+furazolidone 7 days work?
What is Vonoprazan+tetracycline+furazolidone 7 days used for?
Who makes Vonoprazan+tetracycline+furazolidone 7 days?
What drug class is Vonoprazan+tetracycline+furazolidone 7 days in?
What development phase is Vonoprazan+tetracycline+furazolidone 7 days in?
What are the side effects of Vonoprazan+tetracycline+furazolidone 7 days?
Related
- Drug class: All H. pylori eradication therapy (triple therapy) drugs
- Manufacturer: Xijing Hospital of Digestive Diseases — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Infectious Disease
- Indication: Drugs for Helicobacter pylori infection eradication
- Compare: Vonoprazan+tetracycline+furazolidone 7 days vs similar drugs
- Pricing: Vonoprazan+tetracycline+furazolidone 7 days cost, discount & access